文献速递造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

选择性供者CD34(+)细胞输注挽救治疗原发性骨髓纤维化异基因造血干细胞移植后移植物功能不良:3例报告

[Selected donor CD34(+) cell boosts for salvage treatment of poor graft function following allogeneic hematopoietic stem cell transplantation in primary myelofibrosis: 3 cases report].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2024-01-01

回顾性分析上海市闸新中西医结合医院2020年至2023年3例原发性骨髓纤维化患者行异基因造血干细胞移植(allo-HSCT)后发生移植物功能不良并接受选择性供者CD34(+)细胞输注挽救治疗的情况。2例获得血液学恢复,3例均未观察到急性GVHD,1例发生中度口腔慢性GVHD。作者认为该治疗有效且未观察到严重急慢性GVHD。

要点

  • 3例原发性骨髓纤维化allo-HSCT后移植物功能不良患者接受选择性供者CD34(+)细胞输注挽救治疗。
  • 输注后2例获得血液学恢复,3例均未观察到急性GVHD。
  • 1例发生中度口腔慢性GVHD,未观察到严重急慢性GVHD。

核心结论

  • 选择性供者CD34(+)细胞输注治疗原发性骨髓纤维化allo-HSCT后移植物功能不良有效,且未观察到严重的急慢性GVHD。

研究设计与样本

  • 回顾性分析上海市闸新中西医结合医院2020年至2023年行allo-HSCT后发生移植物功能不良并接受供者CD34(+)细胞纯化输注挽救治疗的3例原发性骨髓纤维化患者。
  • 3例中男2例、女1例,中位年龄68(39~69)岁。

主要发现

  • 启动供者CD34(+)细胞纯化输注距allo-HSCT的中位时间为83(56~154)d。
  • 输注的纯化供者CD34(+)细胞中位数7.67(7.61~9.06)×10(6)/kg,CD34(+)细胞纯度97.76%(96.50%~97.91%),回收率70%(42%~75%)。
  • 2例获得血液学恢复;3例患者均未观察到急性GVHD,1例发生口腔慢性GVHD(中度)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A retrospective analysis was conducted on three patients with primary myelofibrosis who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital from 2020 to 2023. They subsequently developed poor graft function. The patients received selected donor CD34(+) cell boosts as salvage therapy. There were two male patients and one female patient, with a median age of 68 (39-69) years. The median time from allo-HSCT to the selected donor CD34(+) cell boost was 83 (56-154) days. The median infusion of selected donor CD34(+) cells was 7.67 (7.61-9.06) ×10(6)/kg, with a CD34(+) cell purity of 97.76% (96.50%-97.91%) and a recovery rate of 70% (42%-75%) . Hematological recovery was achieved in two cases. No acute GVHD was observed in any of the three patients. One case of moderate oral chronic GVHD was noted. Selected donor CD34(+) cell boosts for the treatment of poor graft function after allo-HSCT in primary myelofibrosis was effective and no severe acute or chronic GVHD was observed. 回顾性分析上海市闸新中西医结合医院2020年至2023年行异基因造血干细胞移植(allo-HSCT)后发生移植物功能不良并接受供者CD34(+)细胞纯化输注挽救治疗的3例原发性骨髓纤维化患者,其中男2例,女1例,中位年龄68(39~69)岁。启动供者CD34(+)细胞纯化输注距allo-HSCT的中位时间为83(56~154)d。输注的纯化供者CD34(+)细胞中位数7.67(7.61~9.06)×10(6)/kg,CD34(+)细胞纯度97.76%(96.50%~97.91%),回收率70%(42%~75%),2例获得血液学恢复。3例患者均未观察到急性GVHD,1例发生口腔慢性GVHD(中度)。供者CD34(+)细胞纯化输注治疗原发性骨髓纤维化allo-HSCT后移植物功能不良有效且未观察到严重的急慢性GVHD。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Shi HX, Liu HX, Wei DL, et al. [Selected donor CD34(+) cell boosts for salvage treatment of poor graft function following allogeneic hematopoietic stem cell transplantation in primary myelofibrosis: 3 cases report]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39307728. doi:10.3760/cma.j.cn121090-20240117-00029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。